Difference between revisions of "Adenosquamous carcinoma of the lung"

From Libre Pathology
Jump to navigation Jump to search
Line 4: Line 4:


==General==
==General==
*Respond to [[tyroxine kinase inhibitors]].<ref name=pmid23769878>{{Cite journal  | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref>
*Rare.
*Respond to [[tyrosine kinase inhibitors]].<ref name=pmid23769878>{{Cite journal  | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref><ref namd=pmid23037472>{{Cite journal  | last1 = Iwanaga | first1 = K. | last2 = Sueoka-Aragane | first2 = N. | last3 = Nakamura | first3 = T. | last4 = Mori | first4 = D. | last5 = Kimura | first5 = S. | title = The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib. | journal = Intern Med | volume = 51 | issue = 19 | pages = 2771-4 | month =  | year = 2012 | doi =  | PMID = 23037472 }}</ref>


==Microscopic==
==Microscopic==
Line 17: Line 18:


==References==
==References==
{{Reflist|1}}
{{Reflist|2}}


[[Category:Diagnosis]]
[[Category:Diagnosis]]
[[Category:Lung tumours]]
[[Category:Lung tumours]]

Revision as of 01:44, 9 April 2014

Adenosquamous carcinoma of the lung is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.

It is grouped with the non-small cell lung cancers.

General

Microscopic

Features:

  1. Adenocarcinoma component.
  2. Squamous cell carcinoma component.

See also

References

  1. Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.